ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1576	National Cancer Institute	Html	en	Prostate Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for prostate cancer.	PDQ Screening 0.238955 prostate gland 0.262783 following PDQ summaries 0.255959 Cancer Information Service 0.234967 PDQ cancer information 0.447798 Prevention Editorial Board 0.248763 men 0.210517 National Cancer Institute 0.335949 clinical trials 0.389256 PDQ documents 0.200757 test result 0.223183 benign prostatic hyperplasia 0.273839 cancer information summary 0.326548 newly diagnosed prostate 0.284247 clinical trial 0.213023 new treatment 0.208327 breast cancer prevention 0.217981 early cancer detection 0.236129	Cancer screening trials 0.28054 test 0.242059 Cancer Care page 0.221557 PDQ database 0.205174 prostate cancer gene 0.339499 NCI’s PDQ 0.209119 prostate cancer screening 0.411947 PDQ summary 0.286479 cancer symptoms 0.211597 NCI PDQ cancer 0.287762 prostate cancer 0.971006 tests 0.264624 bigger prostate 0.262229 PSA test 0.20487 Prostate Cancer Prevention 0.350483 cancer information summaries 0.242796 comprehensive cancer information 0.243032 high PSA level 0.200418	CLICK HERE
1580	National Cancer Institute	Html	en	Skin Cancer Screening (PDQ®)–Patient Version	Having a skin exam to screen for skin cancer has not been shown to decrease your chance of dying from skin cancer. Learn about this and other tests that have been studied to detect or screen for skin cancer in this expert reviewed summary.	PDQ Screening 0.323371 skin cancer 0.833312 cancer treatment 0.285886 cancer screening methods 0.360926 United States 0.282138 ongoing clinical trials 0.355632 screening tests 0.287638 cancer cells 0.293854 following PDQ summaries 0.338661 Cancer Information Service 0.328048 PDQ cancer information 0.497713 squamous cells 0.320712 squamous cell skin 0.32842 white men 0.281879 Prevention Editorial Board 0.34433 treatment clinical trials 0.288708 National Cancer Institute 0.431189 clinical trials 0.547197 PDQ documents 0.289835 inner layer 0.288892 test result 0.316842 cancer information summary 0.417477 melanoma skin cancer 0.385616 new treatment 0.294602	breast cancer prevention 0.311531 skin cancer screening 0.419518 Cancer screening trials 0.367401 NCI website 0.290521 Regular skin checks 0.306952 Cancer Care page 0.315809 PDQ database 0.293213 latest published information 0.29227 risk factor 0.309102 NCI’s PDQ 0.299274 PDQ summary 0.314752 UV radiation 0.308073 cancer symptoms 0.303698 doctor 0.289249 NCI PDQ cancer 0.373425 tests 0.320045 cancer information summaries 0.334989 nonmelanoma skin cancer 0.420432 comprehensive cancer information 0.335151 basal cell carcinoma 0.354359 cancer 0.95489 basal cells 0.2875 squamous cell carcinoma 0.357881	CLICK HERE
1600	National Cancer Institute	Html	en	Nutrition in Cancer Care (PDQ®)–Patient Version	Expert-reviewed information summary about the causes and management of nutritional problems that occur in patients with cancer.	cancer treatment 0.815724 foods 0.591336 body 0.50774 PDQ cancer information 0.539768 general health 0.483553 mouth sores 0.564301 nutrition problems 0.511061 cancer information summary 0.514016 Cancer Care section 0.490312 enteral nutrition 0.493173 cancer care 0.499373 cancer patients 0.772982 weight loss 0.581589 dry mouth 0.559356 NCI PDQ cancer 0.489458 nutrition 0.675709 effects 0.559624 good nutrition 0.476052 nutrition therapy 0.671346 radiation therapy 0.583611 Advanced Cancer section 0.512145 nutrition support care 0.489001 cancer treatments 0.531014 parenteral nutrition support 0.491942 cancer prevention 0.486895	cancer cells 0.480334 Cancer Information Service 0.511605 palliative care 0.476957 nutrients 0.514961 certain foods 0.495203 parenteral nutrition 0.492581 National Cancer Institute 0.539267 advanced cancer 0.530168 white blood cell 0.522179 fight infection 0.479873 low white blood 0.494372 breast cancer 0.518198 cancer patients control 0.508745 health 0.485589 food 0.567108 PDQ summary 0.508916 Eat foods 0.503278 following nutrition problems 0.482655 mouth 0.591038 cancer information summaries 0.483904 comprehensive cancer information 0.47883 cancer 0.980934 information 0.558957 Cancer survivors 0.484253	CLICK HERE
1766	National Cancer Institute	Html	en	Accidents at Nuclear Power Plants and Cancer Risk	A fact sheet about cancer risks associated with accidents at nuclear power plants.	Atomic Radiation 0.316376 Radiation risks 0.325562 radiation exposures 0.328269 nuclear accident sites 0.293301 Radiation Research 0.323015 low levels 0.272065 nuclear power plant 0.97677 I-131 exposure 0.297263 radiation sickness 0.405841 high doses 0.352667 radiation emergencies 0.31438 Chernobyl nuclear power 0.302487 Additional radioactive isotopes 0.311741 dangerous radioactive isotopes 0.306851 cancer patients 0.299868 greatest cancer risks 0.294897 cancer risks 0.312758 radioactive materials 0.379547 radiation therapy 0.335122 unstable isotopes 0.274 Radiation Effects Research 0.350011 external radiation 0.312725 power plant disaster 0.278559 radioactive isotopes 0.53284 ionizing radiation 0.412892	health effects 0.355744 future nuclear accidents 0.300229 nuclear reactors 0.284713 power plant accident 0.397996 nuclear weapons explosions 0.282249 thyroid gland 0.292634 thyroid cancer 0.388789 radiation exposure 0.375545 power plant accidents 0.566854 Radiation Emergency Medical 0.344768 I-131 0.306486 radioactive exposure 0.273465 National Cancer Institute 0.340697 specific radioactive materials 0.295979 breast cancer risk 0.282358 Radiation Epidemiology Branch 0.341242 Chernobyl-related thyroid cancer 0.291023 radiation 0.697647 cancer risk 0.309268 et al 0.275755 medical x-ray machines 0.33168 cancer 0.423405 Chernobyl accident 0.42803 certain radioactive isotopes 0.3079	CLICK HERE
1863	National Cancer Institute	Html	es	Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.	cell leukemia treated 0.413444 cell leukemia patients 0.427269 long-term follow-up 0.427434 Rituximab with pentostatin 0.40359 Peaud PY 0.40245 hairy cell leukaemia 0.411122 initially with pentostatin 0.406363 Foucar MK 0.403895 leukemia patients treated 0.417121 leukemia following treatment 0.406508 células pilosas 0.473847 treated with rituximab 0.403745 Instituto Nacional 0.402568 cell leukemia following 0.408562 Else M 0.404329 with pentostatin 0.442439 or refractory hairy 0.403457 VH4-34+ hairy cell 0.404297 Natl Cancer Inst 0.402731 Federico M 0.402782 Leuk Lymphoma 0.424893 long term 0.40908 patients treated with 0.423309 Burian C 0.403658 Matutes E 0.403796	leukemia treated with 0.41301 patients with hairy 0.610395 following treatment with 0.408927 Italian Cooperative Group 0.40697 hairy-cell leukemia with 0.408245 relapsed or refractory 0.403586 National Cancer Institute 0.404377 after treatment with 0.408757 untreated patients with 0.407444 with poor prognosis 0.40323 with 2-CdA 0.403201 cell leukemia with 0.426877 treatment with 0.420376 hairy cell leukemia 0.998262 Clin Oncol 0.444146 treated with pentostatin 0.422653 leukemia with pentostatin 0.404444 leukemia after treatment 0.406381 Long term results 0.402405 treated with 0.429875 treated initially with 0.406289 previously untreated patients 0.40321 PDQ Sofocos 0.402915 cell leukemia after 0.412869	CLICK HERE
1945	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer.	cancer statistics 0.312893 among adult survivors 0.309342 health insurance 0.30576 childhood leukemia survivors 0.314627 Marrow Transplant Survivor 0.306695 largo plazo 0.353459 Cancer Survivor cohort 0.310798 CA Cancer 0.308516 group long-term follow-up 0.307764 mortality among 5-year 0.309974 health conditions 0.3067 young adult cancers 0.387348 late mortality 0.309117 Ness KK 0.312945 among childhood cancer 0.329959 adult survivors 0.341543 Hudson MM 0.322937 among survivors 0.313213 British Childhood Cancer 0.315849 utilization among long-term 0.306183 childhood cancer 0.973475 cancer survivor study 0.608871 late effects 0.312383 SEER Cancer Statistics 0.308306 long-term survivors 0.338777	health care utilization 0.307102 Survivor Study cohort 0.310239 chronic health conditions 0.305835 among adolescent survivors 0.308292 Care Cancer 0.309376 among 5-year survivors 0.328567 Pediatr Blood Cancer 0.42011 oncology group long-term 0.310223 adolescent cancers 0.313982 efectos tardíos 0.375703 survivors research program 0.306998 report from 0.396085 National Cancer Institute 0.308232 Oeffinger KC 0.306859 health care 0.314251 mortality among survivors 0.308816 Clin Oncol 0.375569 childhood cancer survivor 0.872407 medical care 0.307228 among long-term survivors 0.315379 late mortality among 0.306982 long-term follow-up guidelines 0.320022 Outcomes Among Childhood 0.309917 children's oncology group 0.433388	CLICK HERE
2048	National Cancer Institute	Html	es	Pruebas de Papanicolaou y del virus del papiloma humano (VPH)	Hoja informativa que describe los exámenes selectivos de detección del cáncer de cérvix, los cuales incluyen la prueba de Papanicolaou y la prueba de los virus del papiloma humano.	Lancet Oncology 0.30494 alta probabilidad 0.305241 Clinical Pathology 0.316699 siguientes categorías 0.313238 undergoing concurrent testing 0.307924 American Society 0.338185 Schiffman M 0.323335 pruebas conjuntas 0.308272 Sociedad Estadounidense 0.311719 Task Force Recommendation 0.307945 Preventive Services Task 0.350595 Cervical Pathology 0.322689 low-grade squamous 0.308742 Roche Molecular Systems 0.307924 Estados Unidos 0.346024 cervical cancer 0.362845 Clinical Pathology screening 0.309437 cobas hpv test 0.3092 PubMed Abstract 0.387591 categoría cin-2 0.304985 categoría cin-3 0.305133 human papillomavirus 0.356046 Cancer Journal 0.30689 atypical squamous cells 0.360558 Sistema Bethesda 0.324914	Patología Cervical 0.309863 lesiones asc-h 0.305566 categorías cin-2 0.305175 United States Preventive 0.309063 cuidado médico 0.306651 lesiones asc-us 0.30675 Katki HA 0.31204 alto riesgo 0.931083 clinical practice 0.304727 Drug Administration 0.304664 cervical cytology 0.30862 Servicios Preventivos 0.304816 Wacholder S 0.311753 resultado asc-us 0.312665 papillomavirus testing 0.305257 HPV cotesting 0.306351 resultados benignos 0.305213 Services Task Force 0.349973 cervical intraepithelial neoplasia 0.314986 mejores resultados 0.304652 Cancer Institute 0.314518 graves anomalías 0.316853 infecciones pasajeras 0.309673 squamous cell carcinoma 0.313148	CLICK HERE
3876	National Cancer Institute	Html	en	The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)	Apply for the NCI F99/K00 Award that helps late-stage doctoral candidates finish their training and then transition into cancer-focused research positions.	K00 phase institution 0.388613 applicant institution 0.265884 Research Doctoral candidates 0.275389 Funding Opportunity Announcement 0.903132 research supplies 0.244496 Career Development Award 0.350987 k00 award 0.331719 Ph.D. dissertation requirements 0.237088 phase institutional representative 0.335728 project award period 0.253621 indirect costs 0.425626 NCI F99/K00 Predoc 0.307817 Institutional Allowance 0.281782 Career Development Support 0.249362 Research Career Development 0.347168 k00 phase 0.762118 Research Plan section 0.261319 career development skills 0.241364 health-related Ph.D. program 0.243519 F99 primary sponsor 0.23706 Research Service Award 0.312163 Individual Research Career 0.265006 mandatory NCI-sponsored conference 0.307767 Opportunity Announcement instructions 0.260896 career development research 0.317687	dissertation research project 0.396866 Ph.D. degree program 0.256222 valid U.S. visas 0.237157 Postdoctoral Fellow Transition 0.248842 Application Guide 0.311615 NCI Predoctoral 0.237727 F99 phase 0.471921 dissertation research training 0.299174 program staff 0.238571 Program Staff Contact 0.236142 Research Strategy 0.247855 F99/K00 Award 0.359733 F99 grant mechanism 0.235643 assigned NCI Program 0.270275 Development Award Supplemental 0.254853 F99 award 0.269956 fringe benefits 0.272186 valid U.S. visa 0.254123 career development 0.562023 Research Plan Sections 0.252481 Fellowship Applicant Section 0.257658 F99/K00 Award application 0.300758 health-related research field 0.279872 Postdoctoral Research Direction 0.273719	CLICK HERE
15846	National Cancer Institute	Html	en	RAS Biochemistry and Biophysics	This RAS Biochemistry and Biophysics lab investigates signaling by RAS proteins, which is regulated by the interactions with substrates, protein partners, and membranes.	cell membranes 0.473685 Nuclear Magnetic Resonance 0.585708 Biophysics Group team 0.636374 mutant RAS 0.650163 KRAS proteins 0.677168 nanodiscs 0.374828 cancer deaths 0.469996 fully modified KRAS 0.804703 different cancers 0.503399 Washington University 0.469252 analytical ultracentrifugation 0.487353 protein-nanodisc complexes 0.475228 atomic levels 0.48075 stephena@mail.nih.gov 0.45777 Ridge National Laboratory 0.591017 Rodolfo Ghirlando 0.472711 artificial lipid bilayers 0.682865 KRAS4b protein 0.638588 sensitive techniques 0.481762 Carla Mattos 0.458864 California 0.350663 Northeastern University 0.475122 RAS proteins 0.703869 neutron scattering 0.468073 RAS Biochemistry 0.737959	different KRAS 0.64483 different lipid compositions 0.713219 Chris Stanley 0.450409 fully modified KRAS4b 0.914598 Jay Groves 0.463932 interactions 0.440981 intrinsic hydrolysis rates 0.625326 numerous interacting partner 0.64654 inner plasma membrane 0.635847 Marco Tonelli 0.478206 surrogate 0.33572 St. Louis 0.448878 Digestive Kidney Dieases 0.603479 National Institute 0.589812 Paul Henderson 0.462542 single molecule analysis 0.605131 different mutant proteins 0.699255 dozen different mutants 0.686498 biophysical assays 0.484191 binding affinities 0.477155 Steve Sligar 0.461855 biophysics group 0.812528 major oncogenic mutants 0.687098 KRAS account 0.631848	CLICK HERE
17171	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	médico herborista 0.418438 Centro Nacional 0.430037 New Hampshire Avenue 0.420405 Drug Administration 0.412734 NCI Best Case 0.437012 datos bibliográficos pubmed 0.422243 siguientes preguntas 0.413766 demostró efectos 0.424258 siguientes riesgos 0.417668 seguro médico 0.412292 múltiples problemas 0.418438 Instituto Nacional 0.517971 acupuntura ayuda 0.412243 Salud Complementaria 0.450225 Visuals Online 0.415643	complementarias revisa 0.422417 Physician Data Query 0.491682 Estados Unidos 0.863449 actúa pc-spes 0.442835 libre uso 0.415953 suficiente cantidad 0.41905 página manejo 0.414584 ¿El tratamiento 0.421322 Nueva York 0.418373 ¿Los beneficios 0.413162 siguientes medicamentos 0.438285 Series Program 0.413051 medicina complementaria 0.925538 diferentes lotes 0.423892	CLICK HERE